Outset Medical, Inc.
NASDAQ:OMMedical - Devices
+$0.73 today
- Market cap
- $57.31M
- Beta
- 1.94
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$4.07
Volume 0.05M
Average 0.16M
OM Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Outset Medical, Inc.NASDAQ: OM
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit grows, but more slowly than its trailing trend
Q1 FY2026 gross profit of $12.1M rose 9.3% year over year, behind the +15.4% change in trailing-twelve-month gross profit. Sequentially, it fell 1.1% from the prior quarter. Over 3 fiscal years it compounded at +37.9% a year.
Context
- Gross profit amounted to 39.1% of revenue in FY2025, up 5.2 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +9.3% toward the trailing-twelve-month pace of +15.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 46.75M USD
- Year-over-year change
- +21.2%
- 4-year CAGR
- +57.4%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.75M | +21.2% |
| FY2024 | 2024-12-31 | 38.56M | +33.0% |
| FY2023 | 2023-12-31 | 29M | +62.6% |
| FY2022 | 2022-12-31 | 17.83M | +134.4% |
| FY2021 | 2021-12-31 | 7.61M | — |
Gross Profit vs competitors
How OM compares with its peers on the latest reported figures
- OM's LTM Mar 2026 gross profit of $47.78M is the 4th highest of the 10 companies compared; the peer median is $33.55M.
- Its year-over-year change of +15.4% is the 6th highest of 10, against a peer median of +20.2%.
- Gross profit amounts to 40.6% of revenue for OM, versus a peer median of 75.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $171.29M | +9.3% | +2.6% | 48.7% | |
| LTM Mar 2026 | $164.27M | +20.2% | +22.4% | 57.3% | |
| LTM Mar 2026 | $63.93M | -19.3% | +12.6% | 44.1% | |
| LTM Mar 2026 | $47.78M | +15.4% | +37.9% | 40.6% | |
| LTM Mar 2026 | $40.68M | +56.8% | — | 75.5% | |
| LTM Mar 2026 | $33.55M | +21.0% | +39.9% | 75.7% | |
| LTM Mar 2026 | $9.03M | +6284.9% | +157.3% | 94.2% | |
| LTM Mar 2026 | $326K | +115.4% | — | 144.9% | |
| LTM Mar 2026 | -$3.03M | -150.0% | — | 489.8% | |
| LTM Dec 2025 | -$12.79M | -19.4% | — | 98.2% | |
| Peer median (excluding OM) | $33.55M | +20.2% | +22.4% | 75.7% | |
Competitors are the stored peer set for OM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 102.6M | 115.38M | 130.38M | 113.69M | 119.48M |
| Cost of Revenue | 94.99M | 97.54M | 101.38M | 75.13M | 72.72M |
| Gross Profit | 7.61M | 17.83M | 29M | 38.56M | 46.75M |
| Gross Margin | 7.4% | 15.5% | 22.2% | 33.9% | 39.1% |
| Research & Development | 36.74M | 48.86M | 57.31M | 38.4M | 21.24M |
| Selling, General & Admin | 101.39M | 130M | 141.46M | 113.54M | 92.23M |
| Operating Expenses | 138.13M | 178.85M | 198.77M | 151.94M | 113.46M |
| Depreciation & Amortization | 5.16M | 6.28M | 5.81M | 5.73M | 4.34M |
| EBITDA | (124.86M) | (152.81M) | (153.79M) | (97.89M) | (62.37M) |
| EBITDA Margin | -121.7% | -132.4% | -118.0% | -86.1% | -52.2% |
| Operating Income | (130.52M) | (161.02M) | (169.77M) | (113.38M) | (66.71M) |
| Operating Margin | -127.2% | -139.6% | -130.2% | -99.7% | -55.8% |
| Interest Income | 498K | 3.29M | 10.17M | 9.76M | 7.41M |
| Interest Expense | 1.72M | 3.57M | 12.68M | 23.87M | 13.95M |
| Other Income / Expenses | (1.22M) | (1.64M) | (2.5M) | (14.11M) | (14.22M) |
| Income Before Tax | (131.74M) | (162.66M) | (172.27M) | (127.49M) | (80.94M) |
| Pre-Tax Margin | -128.4% | -141.0% | -132.1% | -112.1% | -67.7% |
| Income Tax Expense | 199K | 295K | 523K | 491K | 718K |
| Net Income | (131.94M) | (162.96M) | (172.8M) | (127.98M) | (81.65M) |
| Net Margin | -128.6% | -141.2% | -132.5% | -112.6% | -68.3% |
| EPS (Basic) | (43.41) | (50.75) | (52.27) | (36.95) | (5.37) |
| EPS (Diluted) | (43.41) | (50.75) | (52.27) | (36.95) | (5.37) |
| Weighted Avg Shares | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M |
| Weighted Avg Shares (Diluted) | 3.04M | 3.21M | 3.31M | 3.46M | 15.21M |
Outset Medical, Inc.
NASDAQ:OM
Intrinsic Alpha fair value
Locked
Current Price
$3.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.